Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib.
Investigated for use/treatment in multiple myeloma and solid tumors.
Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Department of Neurology and Center of Integrated Oncology, University Hospital Bonn, Bonn, Germany
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of
Georgetown University- Lombardi Cancer Center, Washington, District of Columbia, United States
Samsung Medical Center, Seoul, Korea, Republic of
Auckland Hospital, Auckland, New Zealand
Northeast Cancer Centre, Health Sciences North, Sudbury, Ontario, Canada
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Juravinski Cancer Centre, Hamilton, Ontario, Canada
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.